Shares of Sun Pharma Advanced Research Company Ltd (SPARC) plunged nearly 20% on Wednesday on the NSE, after the company ...

SPARC tumbled 19 percent after Phase 2 trials of its psoriasis drug SCD-044 failed to meet primary endpoints. The company ...

SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 during trading on the BSE.

Sun Pharma shares are in focus after the company halted its Phase II clinical trial for SCD-044. Meanwhile, Zydus ...

8% of patients maintained that the ongoing war had affected the quality of the treatment they are receiving for psoriasis.

While actives like vitamin C, kojic acid, niacinamide, and alpha arbutin do work, they’re a double-edged sword.

She has had many relapses since, but one in particular was severe. Five years ago she couldn’t move off her right side ...

In this article, we look at two stocks, one from the chemicals sector and another from the pharma sector, recommended by the Trade Brains Portal to buy for an upside potential of more than 22%. We ...

The phototherapy lamps market has been witnessing consistent growth due to increasing global health awareness and the rising demand for non-invasive treatment methods. These specialized lamps, used ...

Indian equity markets recovered on Thursday after falling for two consecutive sessions. The BSE Sensex rose by 320.70 points ...

Does Skipping This Skincare Step Make Sunscreen Less Effective? Dermatologists Weigh In originally appeared on Parade.

Here comes the sunscreen—and the hats, and the protective clothing. For our edit of the year’s very best, we joined forces ...